One marijuana stock expert thinks the market is settling on traditional metrics to evaluate companies in the space following a punishing set of summer months.

As the summer nears its end, the Investing News Network (INN) caught up with Greg Taylor, chief investment officer with Purpose Investments, to discuss the most recent quarterly earnings season and how investors are maturing alongside the marijuana space.

Read on to find out about why Taylor thinks cannabis investing is becoming more difficult as part of this maturity process.

Cannabis industry focusing on “normal metrics”

After extended hype and promotion around marijuana stocks, Taylor said he is seeing a direct shift into valid metrics that can properly capture the growth and development of these companies.

“After many years where everyone was just focusing on big growth plans and putting out flashy press releases, it now seems to be a switch to coming back to operating numbers; we’re focusing more on the cost of sales, we’re talking about normal metrics,” the executive told INN.

Taylor also acts as one of the portfolio managers of the Purpose Marijuana Opportunities Fund (NEO:MJJ).

He explained investors are moving towards only getting influenced by results and performance, a change that Taylor said is welcome in the Canadian cannabis investment market.

“I think (that’s a) big shift that had to come to the sector and it seems like it’s finally here in the Canadian investor,” he said.

As this maturity continues to spread across the Canadian cannabis stock market, the expert said it’s making it more difficult to invest in these names.

“For awhile, I think we were in a phase where people were still excited about the entire sector … you could almost buy any of these companies (and) they would go up and you would be able to make money on them,” Taylor told INN.

“Now that seems to (be) changing … we’re getting a big differentiator between the winners and losers, and the reality is there’s way too many companies in the sector.”

Consolidation in the cannabis market?

When asked if he expects to see shutdowns of existing marijuana companies in Canada, Taylor said he views the market as having no need for this many existing companies.

He anticipates that public companies will survive based on servicing niches that can appeal to investors.

Taylor said he has noticed investors are adding geographic diversity to their investments with regions including the US, Europe and even Asia.

Taylor further noted that the reason investors are looking abroad at some of the emerging companies there is because they offer the potential for a bigger market share and less competition.

However, the portfolio manager said he does not think investors need to completely abandon the Canadian cannabis play.

“Canada got a lot of investor attention because we were the first market to open up; that was unique, and when you have a unique opportunity you get a scarcity premium,” he said.

In short, Taylor is not ready to give up on the Canadian cannabis market, but he is asking for investors to diversify their marijuana portfolios and look at different geographies.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Numinus Bioscience adds Ketamine and LSD to licence to produce, assemble and sell a wide variety of psychedelic compounds

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI ), a global leader in supporting and expanding the safe, accessible and evidence-based use of psychedelic-assisted psychotherapies (PAP), has received new amendments under Canada’s Controlled Drugs and Substances Act that enhance the Company’s ability to lead psychedelics research and support the global psychedelics sector.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact, or

Keep reading... Show less

 INDVR BRANDS INC. (CSE: IDVR) (the “Company” or “INDVR Brands” or “INDVR”), a premier cannabis brand consolidator and producer of Cannabis infused products is pleased to announce the following:

Keep reading... Show less